FDA Staff Unconvinced Drug for Melanoma Shows Benefit

(MedPage Today) -- Another attempt to win accelerated approval for RP1 (vusolimogene oderparepvec)--a melanoma drug candidate that's already been rejected twice by the FDA--could face tough going at a meeting of FDA's outside experts this...